A cell-impermeable cyclosporine a derivative reduces pathology in a mouse model of allergic lung inflammation

Journal of Immunology

Volumn 185, Issue 12, 2010, Pages 7663-7670

  Balsley, Molly A ^a   Malesevic, Miroslav ^b   Stemmy, Erik J ^a   Gigley, Jason ^a   Jurjus, Rosalyn A ^a   Herzog, Dallen ^a   Bukrinsky, Michael I ^a   Fischer, Gunter ^b   Constant, Stephanie L ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b MAX PLANCK RESEARCH UNIT FOR ENZYMOLOGY OF PROTEIN FOLDING   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN; CYCLOSPORIN A [4 N METHYLISOLEUCINE];

ALLERGIC LUNG INFLAMMATION; ALLERGIC LUNG LNFLAMMATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; FEMALE; IMMUNOREGULATION; IN VIVO STUDY; LEUKOCYTE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL;

ANIMALS; ANTIGENS; ASTHMA; CD4-POSITIVE T-LYMPHOCYTES; CYCLOPHILINS; CYCLOSPORINS; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LUNG; MICE; MICE, INBRED BALB C;

EID: 78650655037     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001707     Document Type: Article

References (41)

1. Velazquez, J. R., and L. M. Teran. 2010. Chemokines and their receptors in the allergic airway inflammatory process. Clinic. Rev. Allerg. Immunol. DOI: 10.1007/s12016-010-8202-6.
2. Galat, A. 1993. Peptidylproline cis-trans-isomerases: immunophilins. Eur. J. Biochem. 216:689-707.
3. Wang, P., and J. Heitman. 2005. The cyclophilins. Genome Biol. 6:226.
4. Schiene, C., and G. Fischer. 2000. Enzymes that catalyse the restructuring of proteins. Curr. Opin. Struct. Biol. 10:40-45.
5. Bukrinsky, M. I. 2002. Cyclophilins: unexpected messengers in intercellular communications. Trends Immunol. 23:323-325.
6. Sherry, B., N. Yarlett, A. Strupp, and A. Cerami. 1992. Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide- activated macrophages. Proc. Natl. Acad. Sci. USA 89:3511-3515.
7. Jin, Z. G., M. G. Melaragno, D. F. Liao, C. Yan, J. Haendeler, Y. A. Suh, J. D. Lambeth, and B. C. Berk. 2000. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ. Res. 87:789-796.
8. Allain, F., C. Vanpouille, M. Carpentier, M. C. Slomianny, S. Durieux, and G. Spik. 2002. Interaction with glycosaminoglycans is required for cyclophilin B to trigger integrin-mediated adhesion of peripheral blood T lymphocytes to extracellular matrix. Proc. Natl. Acad. Sci. USA 99:2714-2719.
9. Yurchenko, V., G. Zybarth, M. O'Connor, W. W. Dai, G. Franchin, T. Hao, H. Guo, H. C. Hung, B. Toole, P. Gallay, et al. 2002. Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J. Biol. Chem. 277:22959-22965.
10. Arora, K., W. M. Gwinn, M. A. Bower, A. Watson, I. Okwumabua, H. R. MacDonald, M. I. Bukrinsky, and S. L. Constant. 2005. Extracellular cyclophilins contribute to the regulation of inflammatory responses. J. Immunol. 175:517-522.
11. Billich, A., G. Winkler, H. Aschauer, A. Rot, and P. Peichl. 1997. Presence of cyclophilin A in synovial fluids of patients with rheumatoid arthritis. J. Exp. Med. 185:975-980.
12. Suzuki, J., Z.-G. Jin, D. F. Meoli, T. Matoba, and B. C. Berk. 2006. Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ. Res. 98:811-817.
13. Tegeder, I., A. Schumacher, S. John, H. Geiger, G. Geisslinger, H. Bang, and K. Brune. 1997. Elevated serum cyclophilin levels in patients with severe sepsis. J. Clin. Immunol. 17:380-386.
14. Yurchenko, V., S. Constant, E. Eisenmesser, and M. Bukrinsky. 2010. Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics. Clin. Exp. Immunol. 160:305-317.
15. Handschumacher, R. E., M. W. Harding, J. Rice, R. J. Drugge, and D. W. Speicher. 1984. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 226:544-547.
16. Kallen, J., C. Spitzfaden, M. G. Zurini, G. Wider, H. Widmer, K. Wüthrich, and M. D. Walkinshaw. 1991. Structure of human cyclophilin and its binding site for cyclosporin A determined by X-ray crystallography and NMR spectroscopy. Nature 353:276-279.
17. Ke, H., Y. Zhao, F. Luo, I. Weissman, and J. Friedman. 1993. Crystal structure of murine cyclophilin C complexed with immunosuppressive drug cyclosporin A. Proc. Natl. Acad. Sci. USA 90:11850-11854.
18. Mikol, V., J. Kallen, and M. D. Walkinshaw. 1994. X-ray structure of a cyclophilin B/cyclosporin complex: comparison with cyclophilin A and delineation of its calcineurin-binding domain. Proc. Natl. Acad. Sci. USA 91:5183-5186.
19. Billich, A., F. Hammerschmid, P. Peichl, R. Wenger, G. Zenke, V. Quesniaux, and B. Rosenwirth. 1995. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions. J. Virol. 69:2451-2461.
20. Malesević, M., J. Kühling, F. Erdmann, M. A. Balsley, M. I. Bukrinsky, S. L. Constant, and G. Fischer. 2010. A cyclosporin derivative discriminates between extracellular and intracellular cyclophilins. Angew. Chem. Int. Ed. Engl. 49:213-215.
21. Gwinn, W. M., J. M. Damsker, R. Falahati, I. Okwumabua, A. Kelly-Welch, A. D. Keegan, C. Vanpouille, J. J. Lee, L. A. Dent, D. Leitenberg, et al. 2006. Novel approach to inhibit asthma-mediated lung inflammation using anti-CD147 intervention. J. Immunol. 177:4870-4879.
22. Cohn, L., R. J. Homer, A. Marinov, J. Rankin, and K. Bottomly. 1997. Induction of airway mucus production By T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production. J. Exp. Med. 186:1737-1747.
23. Cormier, S. A., A. G. Taranova, C. Bedient, T. Nguyen, C. Protheroe, R. Pero, D. Dimina, S. I. Ochkur, K. O'Neill, D. Colbert, et al. 2006. Pivotal advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J. Leukoc. Biol. 79:1131-1139.
24. Holgate, S. T., and R. Polosa. 2008. Treatment strategies for allergy and asthma. Nat. Rev. Immunol. 8:218-230.
25. Daum, S., M. Schumann, S. Mathea, T. Aumüller, M. A. Balsley, S. L. Constant, B. F. de Lacroix, F. Kruska, M. Braun, and C. Schiene-Fischer. 2009. Isoformspecific inhibition of cyclophilins. Biochemistry 48:6268-6277.
26. Damsker, J., I. Okwumabua, T. Pushkarsky, K. Arora, M. I. Bukrinsky, and S. L. Constant. 2009. Targeting the chemotactic function of CD147 reduces collagen-induced arthritis. Immunology 126:55-62.
27. Cohn, L., J. A. Elias, and G. L. Chupp. 2004. Asthma: mechanisms of disease persistence and progression. Annu. Rev. Immunol. 22:789-815.
28. Leckie, M. J. 2003. Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models. Am. J. Respir. Med. 2:245-259.
29. Kumar, R. K., C. Herbert, D. C. Webb, L. Li, and P. S. Foster. 2004. Effects of anticytokine therapy in a mouse model of chronic asthma. Am. J. Respir. Crit. Care Med. 170:1043-1048.
30. Wills-Karp, M., J. Luyimbazi, X. Xu, B. Schofield, T. Y. Neben, C. L. Karp, and D. D. Donaldson. 1998. Interleukin-13: central mediator of allergic asthma. Science 282:2258-2261.
31. Walter, D. M., J. J. McIntire, G. Berry, A. N. J. McKenzie, D. D. Donaldson, R. H. DeKruyff, and D. T. Umetsu. 2001. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J. Immunol. 167:4668-4675.
32. Shibata, N., H. Shimakawa, T. Minouchi, and A. Yamaji. 1993. Pharmacokinetics of cyclosporin A after intravenous administration to rats in various disease states. Biol. Pharm. Bull. 16:1130-1135.
33. Ryffel, B., B. M. Foxwell, A. Gee, B. Greiner, G. Woerly, and M. J. Mihatsch. 1988. Cyclosporine: relationship of side effects to mode of action. Transplantation 46 (Suppl.): 90S-96S.
34. Evans, D. J., P. Cullinan, and D. M. Geddes. 2001. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst. Rev. 2: CD002993.
35. Yeum, H. S., Y. C. Lee, S. H. Kim, S. S. Roh, J. C. Lee, and Y. B. Seo. 2007. Fritillaria cirrhosa, Anemarrhena asphodeloides, Lee-Mo-Tang and cyclosporine A inhibit ovalbumin-induced eosinophil accumulation and Th2-mediated bronchial hyperresponsiveness in a murine model of asthma. Basic Clin. Pharmacol. Toxicol. 100:205-213.
36. Fukaya, H., A. Iimura, K. Hoshiko, T. Fuyumuro, S. Noji, and T. Nabeshima. 2003. A cyclosporin A/maltosyl-α-cyclodextrin complex for inhalation therapy of asthma. Eur. Respir. J. 22:213-219.
37. Roh, S. S., S. H. Kim, Y. C. Lee, and Y. B. Seo. 2008. Effects of Radix Adenophorae and cyclosporine A on an OVA-induced murine model of asthma by suppressing to T cells activity, eosinophilia, and bronchial hyperresponsiveness. Mediators Inflamm. 2008:781425.
38. Khan, L. N., O. M. Kon, A. J. Macfarlane, Q. Meng, S. Ying, N. C. Barnes, and A. B. Kay. 2000. Attenuation of the allergen-induced late asthmatic reaction by cyclosporin A is associated with inhibition of bronchial eosinophils, interleukin-5, granulocyte macrophage colony-stimulating factor, and eotaxin. Am. J. Respir. Crit. Care Med. 162:1377-1382.
39. Sihra, B. S., O. M. Kon, S. R. Durham, S. Walker, N. C. Barnes, and A. B. Kay. 1997. Effect of cyclosporin A on the allergen-induced late asthmatic reaction. Thorax 52:447-452.
40. Fukuda, T., J. Asakawa, S. Motojima, and S. Makino. 1995. Cyclosporine A reduces T lymphocyte activity and improves airway hyperresponsiveness in corticosteroid-dependent chronic severe asthma. Ann. Allergy Asthma Immunol. 75:65-72.
41. Polosa, R., and J. Morjaria. 2008. Immunomodulatory and biologic therapies for severe refractory asthma. Respir. Med. 102:1499-1510.